Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Neurodegeneration as an early event in the pathogenesis of diabetic netinopathy. Study of involved mechanisms and new therapeutic strategies

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual, Patricia Bogdanov Baruj
Funding agency: European Foundation for the Study of Diabetes
Funding: 100000
Reference: EFSD-2010-02
Duration: 28/10/2010 - 27/04/2012

Neurodegeneración en la patogénesis de la retinopatía diabética incipiente. Estudio de los mecanismos impllicados a través de un abordaje integrado de biología de sistemas

IP: Rafael Simó Canonge
Collaborators: Dulce María Moncho Rodríguez, Ana Boixadera Espax, Marta Rosal Fontana, Miguel Angel Zapata Victori
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 181500
Reference: SAF2009-07408
Duration: 01/01/2010 - 31/12/2012

Ministerio de Ciencia

Grup de Recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 739
Duration: 01/01/2010 - 30/04/2014

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 247050
Reference: MS08/00058
Duration: 01/02/2009 - 31/01/2015

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Chaysavanh Manichanh

Chaysavanh Manichanh

Head of group
Microbiome Research
Read more
Danila Guagnozzi

Danila Guagnozzi

Physiology and Pathophysiology of the Digestive Tract
Read more
José Salazar Clavijo

José Salazar Clavijo

Research technician
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Stefan Huemmer

Stefan Huemmer

Main researcher
Translational Molecular Pathology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.